|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue: | |||||
| Cost of revenue exclusive of amortization | |||||
| Amortization | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Sales and marketing | |||||
| Product development | |||||
| General and administrative | |||||
| Depreciation and amortization | |||||
| Transaction, integration, and restructuring expenses | |||||
| Goodwill impairment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense), net: | |||||
| Interest income | |||||
| Interest expense | |||||
| Gain on remeasurement of TRA liability | |||||
| Loss on partial extinguishment of debt | |||||
| Other (expense) income, net | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| Benefit from income taxes | |||||
| Net loss | |||||
| Less: Net loss attributable to Definitive OpCo prior to the Reorganization Transactions | |||||
| Less: Net loss attributable to noncontrolling interests | |||||
| Net loss attributable to Definitive Healthcare Corp. | |||||
| Basic | |||||
| Diluted | |||||
| Weighted average common stock outstanding: | |||||
| Basic | |||||
| Diluted | |||||
Loading...